Welcome to our dedicated page for HEMOSTEMIX news (Ticker: HMTXF), a resource for investors and traders seeking the latest updates and insights on HEMOSTEMIX stock.
Hemostemix Inc. (HMTXF) is an autologous stem cell therapy company that has developed a blood-based stem cell therapeutics platform, including angiogenic cell precursors. The company's recent achievements include the successful publication of several peer-reviewed studies on the efficacy of ACP-01 in treating heart disease and chronic limb-threatening ischemia. With a focus on regenerative and cardiac function improvement, Hemostemix aims to provide breakthrough treatments for cardiovascular patients through cutting-edge stem cell therapies.
Rhea-AI Summary
Hemostemix Inc. announces positive Phase II clinical trial results for ACP-01 in treating critical limb ischemia. The trial showed a significant decrease in ulcer size, lower amputation and mortality rates compared to the placebo group. The 1-year death rate in the ACP-01 treatment group was substantially lower than the literature's reported rates. The company plans to produce ACP-01 for revenue and conduct further clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.47%
Tags
-
Rhea-AI Summary
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) closed a private placement of $320,385 with the issuance of 2,669,875 units. The Corporation paid eligible finders aggregate fees of $5,750.40 in cash and issued 47,920 finder options to purchase common shares. The Board of Directors authorized the issuance of 2,375,000 Stock Options at $0.07 each to Directors, Officers, and Consultants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Hemostemix Inc. has announced the publication of its seventh peer-reviewed study on ACP-01 as a treatment for heart disease. The study demonstrates that ACP-01 can regenerate and improve cardiac function in patients with ischemic and non-ischemic dilated cardiomyopathy. The results show an increase in cardiac function of up to 24.1% at 12 months in ischemic cardiomyopathy patients and up to 47.1% at 12 months in non-ischemic cardiomyopathy patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Hemostemix Inc. announces amendment to $2.5 million convertible debenture, resulting in expected interest saving of $569,868.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
-
Rhea-AI Summary
Hemostemix Inc. closed a private placement of $320,125, selling approximately 2.66 Million Units at $0.12 each. Proceeds will be used for production of ACP-01, filing fees, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.02%
Tags
-
Rhea-AI Summary
Hemostemix Inc. announces a new private placement of $325,125, selling approximately 2.7 million units at $0.12 each. Proceeds will be used for production, filing fees, and working capital. Directors may participate in the placement. Additional funds were not received for a second tranche closing. The private placement is subject to regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Hemostemix Inc. announces study of NCP-01 supporting brain computer interfaces submitted for peer review publication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
-
Rhea-AI Summary
Hemostemix Inc. incorporates Hemostemix Quebec Inc. and applies for $6 Million grant funding to locate production of ACP-01 in Montreal. Negotiated terms for a possible shared site to reduce costs. Drafted phase II heart clinical trial protocol. Plans to build out production and generate revenue from the sale of ACP-01.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.56%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.6%
Tags
FAQ
What is the current stock price of HEMOSTEMIX (HMTXF)?
The current stock price of HEMOSTEMIX (HMTXF) is $0.04679 as of December 17, 2024.
What is the market cap of HEMOSTEMIX (HMTXF)?
The market cap of HEMOSTEMIX (HMTXF) is approximately 9.0M.
What does Hemostemix specialize in?
Hemostemix is an autologous stem cell therapy company that has developed a blood-based stem cell therapeutics platform, including angiogenic cell precursors.
What recent achievements has Hemostemix had?
Hemostemix has successfully published several peer-reviewed studies on the efficacy of ACP-01 in treating heart disease and chronic limb-threatening ischemia.
What is the focus of Hemostemix's treatments?
Hemostemix's treatments focus on regenerative and cardiac function improvement, offering breakthrough therapies for cardiovascular patients.
HEMOSTEMIX INC